
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2007

INTERNATIONAL STEM CELL CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other Jurisdiction of
Incorporation)

0-51891

(Commission File Number)

20-4494098

(IRS Employer Identification No.)

**2595 Jason Court
Oceanside, CA**

(Address of Principal Executive Offices)

92056

(Zip Code)

Registrant's telephone number, including area code: **(760) 940-6383**

Not applicable

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 1, 2007, board of directors of International Stem Cell Corporation, a Delaware corporation (the “Company”), elected Don Wright (“Mr. Wright”) to fill a vacancy on the Company’s Board of Directors, to serve until the next annual meeting of stockholders. Mr. Wright is currently President and Founder of Everett, Washington-based Confluence Capital Group Inc. (“Confluence Capital”), which provides consulting services to institutional investors, debt holders and public and private companies. Prior to Confluence Capital, Mr. Wright was President and CEO of Pacific Aerospace & Electronics, Inc. (“Pacific Aerospace”), a company he founded in 1990, took public and ran until 2006. He remains non-Executive Chairman of Pacific Aerospace. Prior to Pacific Aerospace, Mr. Wright was President and CEO of Washington-based Component Concepts, Inc., a company he founded in 1976.

There are no arrangements or understandings between Mr. Wright and any other person pursuant to which he was selected as a director of the Company. Mr. Wright does not have a direct or indirect material interest in any currently proposed transaction to which the Company is a party, nor has Mr. Wright had a direct or indirect material interest in any such transaction during the Company’s last two fiscal years. Attached hereto as Exhibit 99.1, and incorporated herein by reference, is a copy of the Company’s press release dated March 5, 2007, announcing Mr. Wright’s election to the board of directors.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits:

99.1 Press Release, dated March 5, 2007, of International Stem Cell Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTERNATIONAL STEM CELL CORPORATION

Dated: March 4, 2007

By: /s/ Jeff Krstich

Name: Jeff Krstich

Title: Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated March 5, 2007, of International Stem Cell Corporation.

**INTERNATIONAL STEM CELL CORPORATION
NAMES DON WRIGHT TO BOARD OF DIRECTORS**

Oceanside, California, March 5, 2007 – International Stem Cell Corporation (OTCBB: ISCO.OB)

(www.internationalstemcell.com), a California-based, early-stage stem cell therapeutics company, announced today that Don Wright has joined its Board of Directors, effective March 1, 2007.

International Stem Cell Corporation's focus is on the development of stem cell based treatment of diabetes, liver disease and diseases of the retina, and providing specialized cells and media to others for cell based research. It maintains corporate and research facilities in Oceanside, California; production and product development in Walkersville, Maryland; and international research facilities in Moscow, Russia.

Mr. Wright brings to International Stem Cell Corporation over 30 years of experience in starting and nurturing emerging growth companies, both public and private.

He is President and Founder of Everett, Washington-based Confluence Capital Group Inc., (www.confluencecap.com), which provides consulting services to institutional investors, debt holders and public and private companies.

Prior to Confluence Capital, Mr. Wright was President and CEO of Pacific Aerospace & Electronics, Inc., a company he founded in 1990, took public and ran until 2006. He remains non-Executive Chairman of Pacific Aerospace. Under his leadership, Pacific Aerospace grew from annual sales of approximately \$3 million in 1994 to over \$112 million in 2000. Earlier, Mr. Wright was President and CEO of Washington-based Component Concepts, Inc., a company he founded in 1976.

He is the recipient of numerous business and community awards, and was named one of the 50 fastest growing companies in Washington State for 1998, 1999 and 2000 by Deloitte & Touche. Additionally he was recognized by Deloitte & Touche as one of the 500 fastest growing companies in the United States for 1998, 1999 and 2000.

ABOUT INTERNATIONAL STEM CELL CORPORATION:

International Stem Cell is a biotechnology company currently focused on developing therapeutic and research products. In the area of therapeutic product development, ISCO's objective is to create an unlimited source of human cells for use in the treatment of several diseases, including diabetes, liver disease and retinal disease through cell transplant therapy. In furtherance of this objective, ISCO is currently developing human stem cells, techniques to cause those stem cells to be "differentiated" into the specific cell types required for transplant, and manufacturing protocols to produce the cells without contamination with animal by-products, a characteristic likely to be important in meeting U.S. Food and Drug Administration requirements. ISCO also provides the specialized cells and growth media needed for therapeutic cell transplantation research to academic and commercial researchers in related fields. For more information, visit the ISCO website at: www.internationalstemcell.com.

FORWARD LOOKING STATEMENT

This news release contains forward-looking statements relating to the business of ISCO and its subsidiary. Investors are cautioned that such forward-looking statements regarding ISCO, its technology, clinical development and potential applications, constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. International Stem Cell Corporation disclaims any intent or obligation to update these forward-looking statements.

